Acetyl-L-Carnitine and Folic Acid: study protocols
5 study groups took Acetyl-L-Carnitine together with Folic Acid. These are the doses the studies gave. They are not a recommendation.
Dose per serving from research: Acetyl-L-Carnitine
5 study groups in 3 studies say how much Acetyl-L-Carnitine participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 250 mg to 500 mg, 80% of 5 study groups.
| Daily dose | Study groups |
|---|---|
| 250 mg to 500 mg | 4 |
| 500 mg to 1 g | 1 |
Dose per serving from research: Folic Acid
5 study groups in 3 studies say how much Folic Acid participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 250 mcg to 500 mcg, 80% of 5 study groups.
| Daily dose | Study groups |
|---|---|
| 100 mcg to 250 mcg | 1 |
| 250 mcg to 500 mcg | 4 |
Commonly used together
5 of 5 study groups took Acetyl-L-Carnitine and Folic Acid with something else. Shown: what 3 or more different studies gave.
What was given together, not what works together.
| Taken with | Study groups |
|---|---|
| Vitamin B12 | 5 |
5 study groups
| Study | ||||
|---|---|---|---|---|
| Antioxidant treatment for oligoasthenoteratozoospermia and varicocele: a DBPC trial to evaluate the impact of age and body mass index 2024 · supplementation formulation (Proxeed Plus) · Men aged 18–50 years with infertility and oligo-, astheno- and/or teratozoospermia, with or without varicocele | 500 mg | 200 mcg | 26 weeks | — |
| Double-blind, randomised, placebo-controlled trial on the effect of L-carnitine and L-acetylcarnitine on sperm parameters in men with idiopathic oligoasthenozoospermia 2019 · Proxeed Plus · Men aged 19–44 with idiopathic oligoasthenozoospermia and difficulty conceiving with their partners for at least 12 months | 1 g | 400 mcg | 26 weeks | 125 |
| A vitamin/nutriceutical formulation improves memory and cognitive performance in community-dwelling adults without dementia 2010 · NF group, 3-month blinded trial · Community-dwelling adults aged 18–86 years, both sexes, without dementia or clinical memory difficulties | 500 mg | 400 mcg | 90 days | 59 |
| A vitamin/nutriceutical formulation improves memory and cognitive performance in community-dwelling adults without dementia 2010 · Open-label NF group, separate 6-month trial · Community-dwelling adults, both sexes, without dementia or clinical memory difficulties | 500 mg | 400 mcg | 26 weeks | 38 |
| A vitamin/nutriceutical formulation improves memory and cognitive performance in community-dwelling adults without dementia 2010 · NF group, 2-week blinded trial · Community-dwelling adults, both sexes, without dementia or clinical memory difficulties | 500 mg | 400 mcg | 2 weeks | — |